Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART)

Po Liang Lu, Yung Ching Liu, Han Siong Toh, Yu Lin Lee, Yuag Meng Liu, Cheng Mao Ho, Chi Chang Huang, Chun Eng Liu, Wen Chien Ko, Jen Hsien Wang, Hung Jen Tang, Kwok Woon Yu, Yao Shen Chen, Yin Ching Chuang, Yingchun Xu, Yuxing Ni, Yen Hsu Chen, Po Ren Hsueh

研究成果: 雜誌貢獻文章

106 引文 (Scopus)

摘要

In 2009, the Study for Monitoring Antimicrobial Resistance Trends (SMART) was expanded to include surveillance of Gram-negative pathogens causing urinary tract infections (UTIs) in the Asia-Pacific region. A total of 1762 isolates were collected from 38 centers in 11 countries from patients with UTIs in 2009 and 2010. In vitro susceptibilities were determined by the broth microdilution method and susceptibility profiles were determined using minimum inhibitory concentration (MIC) interpretive criteria, as recommended by the Clinical and Laboratory Standards Institute (CLSI) in 2010 (M100-S20), in 2011 (M100-S21), and in 2012 (M100-S22). Enterobacteriaceae comprised 86.0 of the isolates, of which Escherichia coli (56.5) and Klebsiella pneumoniae (13.8) were the two most common species. Amikacin was the most effective antibiotic (91.7), followed by ertapenem (86.9), imipenem (86.6), and piperacillin-tazobactam (84.9). Rates of susceptibility were 50.3 for cefoxitin and ranged from 50.3 to 74.2 for the third- and fourth-generation cephalosporins. For ciprofloxacin and levofloxacin, the susceptibility rates were 51.4 and 54.4, respectively. Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae comprised 28.2 of all isolates. We also found a high rate of resistance to carbapenems among Acinetobacter baumannii and Pseudomonas aeruginosa causing UTI. Interestingly, according to 2012 CLSI breakpoints, approximately 33.4 of ESBL producers were still susceptible to ceftazidime. However, this in vitro efficacy of ceftazidime needs to be validated in vivo by clinical data. The lowered CLSI interpretive breakpoints for piperacillin-tazobactam, carbapenems, and some cephalosporins in 2011-2012 for Enterobacteriaceae resulted in an approximate 5 drop in susceptibility rates for each drug, with the exception of imipenem for which the susceptibility rate dropped from 99.4 according to 2010 criteria to 91.2 according to 2011 criteria. With the updated CLSI criteria, the antimicrobial resistance threat from UTI pathogens in the Asia Pacific area was revealed to be more prominent.
原文英語
期刊International Journal of Antimicrobial Agents
40
發行號SUPPL. 1
DOIs
出版狀態已發佈 - 六月 2012

指紋

Gram-Negative Bacteria
Urinary Tract Infections
Epidemiology
Enterobacteriaceae
Carbapenems
Ceftazidime
Imipenem
Cephalosporins
Cefoxitin
Acinetobacter baumannii
Levofloxacin
Amikacin
Klebsiella pneumoniae
Microbial Sensitivity Tests
Ciprofloxacin
Pseudomonas aeruginosa
Escherichia coli
Anti-Bacterial Agents
Pharmaceutical Preparations
tazobactam drug combination piperacillin

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases
  • Pharmacology (medical)

引用此文

Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region : 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). / Lu, Po Liang; Liu, Yung Ching; Toh, Han Siong; Lee, Yu Lin; Liu, Yuag Meng; Ho, Cheng Mao; Huang, Chi Chang; Liu, Chun Eng; Ko, Wen Chien; Wang, Jen Hsien; Tang, Hung Jen; Yu, Kwok Woon; Chen, Yao Shen; Chuang, Yin Ching; Xu, Yingchun; Ni, Yuxing; Chen, Yen Hsu; Hsueh, Po Ren.

於: International Journal of Antimicrobial Agents, 卷 40, 編號 SUPPL. 1, 06.2012.

研究成果: 雜誌貢獻文章

Lu, Po Liang ; Liu, Yung Ching ; Toh, Han Siong ; Lee, Yu Lin ; Liu, Yuag Meng ; Ho, Cheng Mao ; Huang, Chi Chang ; Liu, Chun Eng ; Ko, Wen Chien ; Wang, Jen Hsien ; Tang, Hung Jen ; Yu, Kwok Woon ; Chen, Yao Shen ; Chuang, Yin Ching ; Xu, Yingchun ; Ni, Yuxing ; Chen, Yen Hsu ; Hsueh, Po Ren. / Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region : 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). 於: International Journal of Antimicrobial Agents. 2012 ; 卷 40, 編號 SUPPL. 1.
@article{4e5f59e4e9b9490ead2c255437fa2c98,
title = "Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART)",
abstract = "In 2009, the Study for Monitoring Antimicrobial Resistance Trends (SMART) was expanded to include surveillance of Gram-negative pathogens causing urinary tract infections (UTIs) in the Asia-Pacific region. A total of 1762 isolates were collected from 38 centers in 11 countries from patients with UTIs in 2009 and 2010. In vitro susceptibilities were determined by the broth microdilution method and susceptibility profiles were determined using minimum inhibitory concentration (MIC) interpretive criteria, as recommended by the Clinical and Laboratory Standards Institute (CLSI) in 2010 (M100-S20), in 2011 (M100-S21), and in 2012 (M100-S22). Enterobacteriaceae comprised 86.0 of the isolates, of which Escherichia coli (56.5) and Klebsiella pneumoniae (13.8) were the two most common species. Amikacin was the most effective antibiotic (91.7), followed by ertapenem (86.9), imipenem (86.6), and piperacillin-tazobactam (84.9). Rates of susceptibility were 50.3 for cefoxitin and ranged from 50.3 to 74.2 for the third- and fourth-generation cephalosporins. For ciprofloxacin and levofloxacin, the susceptibility rates were 51.4 and 54.4, respectively. Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae comprised 28.2 of all isolates. We also found a high rate of resistance to carbapenems among Acinetobacter baumannii and Pseudomonas aeruginosa causing UTI. Interestingly, according to 2012 CLSI breakpoints, approximately 33.4 of ESBL producers were still susceptible to ceftazidime. However, this in vitro efficacy of ceftazidime needs to be validated in vivo by clinical data. The lowered CLSI interpretive breakpoints for piperacillin-tazobactam, carbapenems, and some cephalosporins in 2011-2012 for Enterobacteriaceae resulted in an approximate 5 drop in susceptibility rates for each drug, with the exception of imipenem for which the susceptibility rate dropped from 99.4 according to 2010 criteria to 91.2 according to 2011 criteria. With the updated CLSI criteria, the antimicrobial resistance threat from UTI pathogens in the Asia Pacific area was revealed to be more prominent.",
keywords = "Asia-Pacific region, Carbapenems, Extended-spectrum β-lactamase (ESBL), Fluoroquinolone resistance, Interpretive susceptibility criteria, SMART, Urinary tract infections",
author = "Lu, {Po Liang} and Liu, {Yung Ching} and Toh, {Han Siong} and Lee, {Yu Lin} and Liu, {Yuag Meng} and Ho, {Cheng Mao} and Huang, {Chi Chang} and Liu, {Chun Eng} and Ko, {Wen Chien} and Wang, {Jen Hsien} and Tang, {Hung Jen} and Yu, {Kwok Woon} and Chen, {Yao Shen} and Chuang, {Yin Ching} and Yingchun Xu and Yuxing Ni and Chen, {Yen Hsu} and Hsueh, {Po Ren}",
year = "2012",
month = "6",
doi = "10.1016/S0924-8579(12)70008-0",
language = "English",
volume = "40",
journal = "International Journal of Antimicrobial Agents",
issn = "0924-8579",
publisher = "Elsevier",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region

T2 - 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART)

AU - Lu, Po Liang

AU - Liu, Yung Ching

AU - Toh, Han Siong

AU - Lee, Yu Lin

AU - Liu, Yuag Meng

AU - Ho, Cheng Mao

AU - Huang, Chi Chang

AU - Liu, Chun Eng

AU - Ko, Wen Chien

AU - Wang, Jen Hsien

AU - Tang, Hung Jen

AU - Yu, Kwok Woon

AU - Chen, Yao Shen

AU - Chuang, Yin Ching

AU - Xu, Yingchun

AU - Ni, Yuxing

AU - Chen, Yen Hsu

AU - Hsueh, Po Ren

PY - 2012/6

Y1 - 2012/6

N2 - In 2009, the Study for Monitoring Antimicrobial Resistance Trends (SMART) was expanded to include surveillance of Gram-negative pathogens causing urinary tract infections (UTIs) in the Asia-Pacific region. A total of 1762 isolates were collected from 38 centers in 11 countries from patients with UTIs in 2009 and 2010. In vitro susceptibilities were determined by the broth microdilution method and susceptibility profiles were determined using minimum inhibitory concentration (MIC) interpretive criteria, as recommended by the Clinical and Laboratory Standards Institute (CLSI) in 2010 (M100-S20), in 2011 (M100-S21), and in 2012 (M100-S22). Enterobacteriaceae comprised 86.0 of the isolates, of which Escherichia coli (56.5) and Klebsiella pneumoniae (13.8) were the two most common species. Amikacin was the most effective antibiotic (91.7), followed by ertapenem (86.9), imipenem (86.6), and piperacillin-tazobactam (84.9). Rates of susceptibility were 50.3 for cefoxitin and ranged from 50.3 to 74.2 for the third- and fourth-generation cephalosporins. For ciprofloxacin and levofloxacin, the susceptibility rates were 51.4 and 54.4, respectively. Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae comprised 28.2 of all isolates. We also found a high rate of resistance to carbapenems among Acinetobacter baumannii and Pseudomonas aeruginosa causing UTI. Interestingly, according to 2012 CLSI breakpoints, approximately 33.4 of ESBL producers were still susceptible to ceftazidime. However, this in vitro efficacy of ceftazidime needs to be validated in vivo by clinical data. The lowered CLSI interpretive breakpoints for piperacillin-tazobactam, carbapenems, and some cephalosporins in 2011-2012 for Enterobacteriaceae resulted in an approximate 5 drop in susceptibility rates for each drug, with the exception of imipenem for which the susceptibility rate dropped from 99.4 according to 2010 criteria to 91.2 according to 2011 criteria. With the updated CLSI criteria, the antimicrobial resistance threat from UTI pathogens in the Asia Pacific area was revealed to be more prominent.

AB - In 2009, the Study for Monitoring Antimicrobial Resistance Trends (SMART) was expanded to include surveillance of Gram-negative pathogens causing urinary tract infections (UTIs) in the Asia-Pacific region. A total of 1762 isolates were collected from 38 centers in 11 countries from patients with UTIs in 2009 and 2010. In vitro susceptibilities were determined by the broth microdilution method and susceptibility profiles were determined using minimum inhibitory concentration (MIC) interpretive criteria, as recommended by the Clinical and Laboratory Standards Institute (CLSI) in 2010 (M100-S20), in 2011 (M100-S21), and in 2012 (M100-S22). Enterobacteriaceae comprised 86.0 of the isolates, of which Escherichia coli (56.5) and Klebsiella pneumoniae (13.8) were the two most common species. Amikacin was the most effective antibiotic (91.7), followed by ertapenem (86.9), imipenem (86.6), and piperacillin-tazobactam (84.9). Rates of susceptibility were 50.3 for cefoxitin and ranged from 50.3 to 74.2 for the third- and fourth-generation cephalosporins. For ciprofloxacin and levofloxacin, the susceptibility rates were 51.4 and 54.4, respectively. Extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae comprised 28.2 of all isolates. We also found a high rate of resistance to carbapenems among Acinetobacter baumannii and Pseudomonas aeruginosa causing UTI. Interestingly, according to 2012 CLSI breakpoints, approximately 33.4 of ESBL producers were still susceptible to ceftazidime. However, this in vitro efficacy of ceftazidime needs to be validated in vivo by clinical data. The lowered CLSI interpretive breakpoints for piperacillin-tazobactam, carbapenems, and some cephalosporins in 2011-2012 for Enterobacteriaceae resulted in an approximate 5 drop in susceptibility rates for each drug, with the exception of imipenem for which the susceptibility rate dropped from 99.4 according to 2010 criteria to 91.2 according to 2011 criteria. With the updated CLSI criteria, the antimicrobial resistance threat from UTI pathogens in the Asia Pacific area was revealed to be more prominent.

KW - Asia-Pacific region

KW - Carbapenems

KW - Extended-spectrum β-lactamase (ESBL)

KW - Fluoroquinolone resistance

KW - Interpretive susceptibility criteria

KW - SMART

KW - Urinary tract infections

UR - http://www.scopus.com/inward/record.url?scp=84863501931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863501931&partnerID=8YFLogxK

U2 - 10.1016/S0924-8579(12)70008-0

DO - 10.1016/S0924-8579(12)70008-0

M3 - Article

C2 - 22749057

AN - SCOPUS:84863501931

VL - 40

JO - International Journal of Antimicrobial Agents

JF - International Journal of Antimicrobial Agents

SN - 0924-8579

IS - SUPPL. 1

ER -